middle.news
Argent BioPharma Secures A$11m to Complete AusCann Deal and Eye US Listing
9:51am on Monday 17th of November, 2025 AEDT
•
Healthcare
Read Story
Argent BioPharma Secures A$11m to Complete AusCann Deal and Eye US Listing
9:51am on Monday 17th of November, 2025 AEDT
Key Points
A$11 million convertible securities facility secured from US-based C/M Capital
Acquisition of AusCann assets including Neuvis drug delivery and EU-GMP manufacturing
Access to German pharma distribution network via ECC Pharm stake
Board reshuffle with Roby Zomer moving to Non-Executive Chairman
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RGT
OPEN ARTICLE